A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of PV-10 Chemoablation of Cancer Metastatic to the Liver or Hepatocellular Carcinoma Not Amenable to Resection or Transplant
Latest Information Update: 15 Nov 2023
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Rose bengal sodium (Primary)
- Indications Liver cancer; Liver metastases; Neuroendocrine tumours; Uveal melanoma
- Focus Adverse reactions
- Sponsors Provectus Biopharmaceuticals
Most Recent Events
- 13 Nov 2023 Results presented in a Provectus Biopharmaceuticals Media Release.
- 01 Aug 2023 According to a Provectus Biopharmaceuticals media release, data from this study will be presented at the Society for Melanoma Research (SMR) 2023 Congress (the SMR annual meeting)
- 31 Oct 2022 Status changed from recruiting to active, no longer recruiting.